Hannah Boland

Hannah Boland is a business journalist at The Telegraph, covering retail, food and pharmaceutical industries. She has reported on the impact of weight-loss drugs on consumers and the businesses that profit from them. Prior to joining The Telegraph, she worked as a reporter for Sky News where she covered stories related to high street retailers and consumer trends.

Biography:  https://www.telegraph.co.uk/authors/h/ha-he/hannah-boland/

85%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermines the credibility of the source. It is calculated as:
Analysis.OverallConflictOfInterestScore * 0.3F + Analysis.OverallBiasScore * 0.3F + Analysis.DeceptivenessScore * 0.3F + Analysis.ReadabilityScore * 0.1F

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

The Daily's Verdict

This author has a mixed reputation for journalistic standards. It is advisable to fact-check, scrutinize for bias, and check for conflicts of interest before relying on the author's reporting.

Bias

88%

Examples:

  • gauntness
  • Ozempic face horror
  • rapid weight loss trend leaves users with sagging skin
  • Sharon Osbourne said last year she thought she had become 'too gaunt'

Conflicts of Interest

100%

Examples:

No current examples available.

Contradictions

100%

Examples:

No current examples available.

Deceptions

65%

Examples:

  • Competition to get customers to spend on reversing weight-loss drugs’ effect on their faces is expected to be significant.
  • The growing number of those on obesity drugs are less relaxed about the sudden loss of weight in their face – a phenomenon known as 'Ozempic face', where people report having sunken cheeks and sagging skin on their faces after shedding the pounds.

Recent Articles

GLP-1 Drugs: A Step Forward in Obesity Care but Not a Silver Bullet

GLP-1 Drugs: A Step Forward in Obesity Care but Not a Silver Bullet

Broke On: Wednesday, 10 July 2024 GLP-1 drugs like Ozempic and Wegovy offer weight loss benefits and health improvements, but they don't address the systemic issues in obesity care. A survey by Verywell Health revealed that many people face barriers to respectful care. Dr. Fatima Cody Stanford's research revolutionized obesity medicine with approved diabetes drugs for treating obesity. However, these drugs are not a long-term solution for weight loss or addressing underlying issues contributing to obesity.